Edition:
United States

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

2.01USD
3:59pm EST
Change (% chg)

$-0.19 (-8.64%)
Prev Close
$2.20
Open
$2.27
Day's High
$2.27
Day's Low
$2.01
Volume
48,050
Avg. Vol
59,030
52-wk High
$22.16
52-wk Low
$2.01

Select another date:

Fri, Dec 8 2017

BRIEF-Akari Therapeutics Says Mid-stage Trial Of Coversin In Patients With Rare Blood Disease PNH Successful

* AKARI THERAPEUTICS ANNOUNCES PHASE II COBALT TRIAL OF COVERSIN™ IN PATIENTS WITH PNH MET THE PRIMARY ENDPOINT

BRIEF-Akari Therapeutics proposes public offering of ADS

* Akari Therapeutics announces proposed public offering of American Depositary Shares Source text for Eikon: Further company coverage:

BRIEF-Akari Therapeutics announces further clinical progress

* Akari Therapeutics - 3 additional patients have been enrolled in ongoing Phase II Cobalt clinical trial of Coversin in patients with PNH​

BRIEF-Akari ‍plans to advance its lead drug, Coversin towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria in Q1 2018​

* ‍plans to advance its lead drug, Coversin towards Phase III clinical studies in paroxysmal nocturnal hemoglobinuria in Q1 2018​

Select another date: